Mirati Therapeutics (NASDAQ:MRTX) Given New $62.00 Price Target at Oppenheimer

Mirati Therapeutics (NASDAQ:MRTX – Free Report) had its target price lifted by Oppenheimer from $56.00 to $62.00 in a research report released on Wednesday morning, MarketBeat reports. They currently have an outperform rating on the biotechnology company’s stock. MRTX has been the subject of a number of other reports. BMO Capital Markets decreased their price […]

Related Keywords

United States ,America ,Jamie Christensen ,Laurie Stelzer ,Granahan Investment Management ,Edmond De Rothschild Holding ,Mirati Therapeutics Company Profile ,Advisors Inc ,Fiera Capital Corp ,Scotiabank ,Mirati Therapeutics Inc ,Mirati Therapeutics ,Free Report ,Get Free Report ,Capital Corp ,Mirati Therapeutics Daily ,Nasdaq Mrtx ,Mrtx ,Medical ,Boost Price Target ,Oppenheimer Holdings Inc ,